Recent progress in rheumatoid arthritis genetics: one step towards improved patient care.
OBJECTIVE
Recent human genetic discoveries have increased our understanding of rheumatoid arthritis (RA) susceptibility. These discoveries are reviewed and placed in the context of potential important clinical applications.


RESULTS
Genome-wide association studies and related methodologies have expanded the number of validated RA risk loci beyond HLA-DRB1 'shared epitope' alleles to include additional major histocompatibility complex risk alleles and more than 10 regions outside the major histocompatibility complex locus. The newly discovered risk alleles are common in the general population, and most have a modest effect on risk of RA (odds ratio approximately 1.15 per copy of each risk allele). Although the actual causal mutation and causal gene for most loci remain to be determined, these studies are beginning to reveal general themes: many risk loci are associated with other autoimmune diseases, many genes fall within discrete biological pathways (e.g., the NF-kappaB signaling pathway), and human genetics can subset disease into clinically meaningful categories (e.g., presence or absence of autoantibodies).


CONCLUSIONS
Approximately one-third of the genetic basis of RA can be explained by known risk loci. Future studies need to pinpoint the actual causal mutations, expand the number of risk loci, and translate these discoveries to improve care of patients with RA.
Plenge
Robert M
RM
Division of Rheumatology, Immunology and Allergy, Brigham and Women's, Hospital, Harvard Medical School, Boston, USA. rplenge@partners.org
D000483:Alleles; D001172:Arthritis, Rheumatoid / Q000235:genetics* / Q000276:immunology / Q000628:therapy; D015551:Autoimmunity / Q000235:genetics; D019013:CD40 Antigens / Q000235:genetics; D005006:Ethnicity / Q000235:genetics; D018628:Gene Dosage; D020022:Genetic Predisposition to Disease; D014644:Genetic Variation; D055106:Genome-Wide Association Study; D006684:HLA-DR Antigens / Q000235:genetics; D059811:HLA-DRB1 Chains; D006801:Humans; D007125:Immunogenetics; D008957:Models, Genetic; D016328:NF-kappa B / Q000235:genetics; D010456:Peptides, Cyclic / Q000235:genetics; D012307:Risk Factors
D019013:CD40 Antigens; D006684:HLA-DR Antigens; D059811:HLA-DRB1 Chains; D016328:NF-kappa B; D010456:Peptides, Cyclic; C487763:cyclic citrullinated peptide